Author

Maxim C.‐J. Cheeran

University of MinnesotaORCID 0000-0002-5331-4746Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Benjamin T. Zandstra· 1 shared Carly BaehriD· 1 shared Dustin HicksiD· 1 shared Geoffrey T. HartiD· 1 shared J. Sjef VerbeekiD· 1 shared Jenna K. DickiD· 1 shared Jules A. SangalaiD· 1 shared Marco PravetoniiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Benjamin T. Zandstra

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2

Jenna K. Dick, Venkatramana Divana Krishna, Dustin Hicks, Jules A. Sangala, Robert J. Oldham, Benjamin T. Zandstra, Carly Baehr, J. Sjef Verbeek, Mark Steven Cragg, Marco Pravetoni, Maxim C.‐J. Cheeran, Geoffrey T. Hart

This study shows that Fc receptor engagement is necessary for the efficacy of SARS-CoV-2 therapeutics, including mAbs and BiKEs, and demonstrates the effectiveness of ACE2 decoy Fc-fusions and BiKEs against multiple variants.

The Journal of Immunology · Aug 1, 2026Peer-reviewedImmunology